Gujarat Themis Biosyn Limited — Board Meeting, 01-08-2025: Outcome of Board Meeting

Gujarat Themis Biosyn's board has announced its Q1 standalone financial results, reporting a net profit of ₹9.06 Cr. In a major strategic shift, the company will not proceed with the proposed merger with Themis Medicare Limited, opting instead to focus on its core fermentation-based pharmaceutical business. A key operational update is the new state-of-the-art Vapi API plant, which began commercial production on May 1, supporting future growth and exports. The record date for the FY25 dividend is set for September 5. The board also appointed Mr. Nihar Parikh as an Additional Non-Executive Independent Director.